Active substance
Results for the substance lutetium (177lu) oxodotreotide
1 result
About this active substance
Lutetium (177Lu) oxodotreotide is a radiopharmaceutical used for the treatment of well-differentiated neuroendocrine tumors that express somatostatin receptors. It works by emitting beta radiation, destroying tumor cells.
The medication is administered intravenously, usually as part of a treatment cycle involving multiple sessions, under the supervision of a nuclear medicine specialist. Monitoring of renal and hematologic function is important during treatment.
Side effects may include nausea, vomiting, fatigue, or a decrease in blood cell counts. In rare cases, renal failure or severe allergic reactions may occur.
Lutetium (177Lu) oxodotreotide is not recommended for patients with severe renal impairment or for pregnant women. Adherence to safety measures for handling radioactive materials is essential.
The medication is administered intravenously, usually as part of a treatment cycle involving multiple sessions, under the supervision of a nuclear medicine specialist. Monitoring of renal and hematologic function is important during treatment.
Side effects may include nausea, vomiting, fatigue, or a decrease in blood cell counts. In rare cases, renal failure or severe allergic reactions may occur.
Lutetium (177Lu) oxodotreotide is not recommended for patients with severe renal impairment or for pregnant women. Adherence to safety measures for handling radioactive materials is essential.